Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HeadSTART: Tirapazamine with Chemoradiation in Advanced Head and Neck Cancer
NCT00094081Phase 3Completed
- Sponsor
- Sanofi
- Start
- Oct 2002
- Primary completion
- Sep 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of tirapazamine in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by Sanofi. Primary endpoint: Overall Survival at 2 years. Started Oct 2002; status: completed.
02
Drugs
tirapazamine
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT00094081.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00094081.